Hostname: page-component-8448b6f56d-mp689 Total loading time: 0 Render date: 2024-04-24T01:13:55.565Z Has data issue: false hasContentIssue false
  • English
  • Français

Neuroleptic Malignant Syndrome and Psychotic Illness

Published online by Cambridge University Press:  02 January 2018

Adityanjee ,
P. Das  and
H. M. Chawla
Adityanjee*
Affiliation:
Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India
P. Das
Affiliation:
Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India
H. M. Chawla
Affiliation:
Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India
*
∗Registrar in Psychiatry, The Maudsley Hospital, Denmark Hill, London SE5 8AZ
Get access Rights & Permissions [Opens in a new window]

Abstract

A typical case of NMS and its successful treatment with bromocriptine is described. The authors noticed an inverse relationship between the process of recovery from NMS and the pre-existing psychotic illness.

Type
Brief Reports
Information
The British Journal of Psychiatry , Volume 155 , Issue 6 , December 1989 , pp. 852 - 854
Copyright
Copyright © The Royal College of Psychiatrists, 1989 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adityanjee, , Singh, S., Singh, G., et al (1988) Spectrum concept of neuroleptic malignant syndrome. British Journal of Psychiatry; 153, 107–111.Google Scholar
Ansseau, M., Reynolds, C. F., Kupfer, D. J., et al (1986) Central dopaminergic and noradrenergic receptor blockade in a patient with neuroleptic malignant syndrome. Journal of Clinical Psychiatry, 47, 320–321.Google Scholar
Hashimoto, F., Sherman, C. B. & Jeffery, W. H. (1984) Neuroleptic malignant syndrome and dopaminergic blockade. Archives of Internal Medicine, 144, 629–630.CrossRefGoogle ScholarPubMed
Hermesh, H., Huberman, M., Radvan, H., et al (1985) Recurrent neuroleptic malignant syndrome due to tiapride and haloperidol: the possible role of D-2 dopamine receptor blockade. Archives of Internal Medicine, 144, 629–630.Google Scholar
Levenson, J. L. (1985) Neuroleptic malignant syndrome. American Journal of Psychiatry, 142, 1137–1145.Google ScholarPubMed
Levenson, J. L. & Fisher, J. G. (1988) Long-term outcome after neuroleptic malignant syndrome. Journal of Clinical Psychiatry, 49, 154–156.Google Scholar
Mueller, P. S. (1985) Neuroleptic malignant syndrome. Psychosomatics, 26, 654–662.CrossRefGoogle ScholarPubMed
Mueller, P. S. (1986) Diagnosing and defining neuroleptic malignant syndrome. American Journal of Psychiatry, 143, 673–674.Google Scholar
Shalev, A. & Munitz, H. (1986) The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatrica Scandinavica, 73, 337–347.Google Scholar
Susman, V. L. & Addnizio, G. L. (1988) Recurrence of neuroleptic malignant syndrome. Journal of Nervous and Mental Disease, 176, 234–240.Google Scholar
Toru, M., Matsuda, O., Makiguchi, K., et al (1981) Neuroleptic malignant syndrome-like state following a withdrawal of anti-parkinsonian drugs. Journal of Nervous and Mental Disease, 169, 324–327.Google Scholar
World Health Organization (1978) Mental Disorders: Glossary and Guide to their Classification in Accordance with the Ninth Revision of the International Classification of Diseases (ICD-9). Geneva: WHO.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.